About: Secondary myopathy due to systemic diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Secondary myopathy due to systemic diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Secondary myopathy due to systemic diseases
source	Medline; PMC
abstract	BACKGROUND: Some systemic diseases also affect the skeletal muscle to various degrees and with different manifestations. This review aimed at summarizing and discussing recent advances concerning the management of muscle disease in systemic diseases. METHOD: Literature review by search of MEDLINE, and Current Contents with appropriate search terms. RESULTS: Secondary muscle disease occurs in infectious disease, endocrine disorders, metabolic disorders, immunological disease, vascular diseases, hematological disorders, and malignancies. Muscle manifestations in these categories include pathogen‐caused myositis, muscle infarction, rhabdomyolysis, myasthenia, immune‐mediated myositis, necrotising myopathy, or vasculitis‐associated myopathy. Muscle affection may concern only a single muscle, a group of muscles, or the entire musculature. Severity of muscle affection may be transient or permanent, may be a minor part of or may dominate the clinical picture, or may be mild or severe, requiring invasive measures including artificial ventilation if the respiratory muscles are additionally involved. Diagnostic work‐up is similar to that of primary myopathies by application of non‐invasive and invasive techniques. Treatment of muscle involvement in systemic diseases is based on elimination of the underlying cause and supportive measures. The prognosis is usually fair if the causative disorder is effectively treatable but can be fatal in single cases if the entire musculature including the respiratory muscles is involved, in case of infection, or in case of severe rhabdomyolysis. CONCLUSION: Secondary muscle manifestations of systemic diseases must be addressed and appropriately managed. Prognosis of secondary muscle disease in systemic diseases is usually fair if the underlying condition is accessible to treatment.
has issue date	2016-02-25(xsd:dateTime)
bibo:doi	10.1111/ane.12576
bibo:pmid	26915593
has license	no-cc
sha1sum (hex)	bc13469ce977e06ce2e83b3645642e709f00d061
schema:url	https://doi.org/10.1111/ane.12576
resource representing a document's title	Secondary myopathy due to systemic diseases
has PubMed Central identifier	PMC7159623
has PubMed identifier	26915593
schema:publication	Acta Neurol Scand
resource representing a document's body	covid:bc13469ce977e06ce2e83b3645642e709f00d061#body_text
is schema:about of	named entity 'dermatomyositis' named entity 'sedentarism' named entity 'Leukemia' named entity 'diabetes' named entity 'myositis' named entity 'myopathy' named entity 'rhabdomyolysis' named entity 'capillaries' named entity 'tRNA' named entity 'myokymia' named entity 'myopathy' named entity 'myositis' named entity 'overlap syndrome' named entity 'myositis' named entity 'dermatomyositis' named entity 'muscle disease' named entity 'sickle cell anemia' named entity 'infection' named entity 'Viral infections' named entity 'muscle fatigue' named entity 'polymyositis' named entity 'myogenin' named entity 'myositis' named entity 'abscess' named entity 'atrophy' named entity 'intestines' named entity 'brucella' named entity 'pathogen' named entity 'myalgia' named entity 'compartment syndrome' named entity 'toxoplasma' named entity 'small arteries' named entity 'viral infections' named entity 'anti-Jo1' named entity 'vasculitic' named entity 'Pyomyositis' named entity 'Muscle' named entity 'Infection' named entity 'infection' named entity 'Rhabdomyolysis' named entity 'myopathy' named entity 'dengue' named entity 'open label' named entity 'myositis' named entity 'perfusion' named entity 'rhabdomyolysis' named entity 'Haycocknema perplexum' named entity 'rhabdomyolysis' named entity 'muscle biopsy' named entity 'tumor' named entity 'gene' named entity 'purulent' named entity 'neurologist' named entity 'contractures' named entity 'systemic diseases' named entity 'CMV' named entity 'polymyositis' named entity 'overlap syndrome' named entity 'rhabdomyolysis' named entity 'Helminthes' named entity 'necrosis' named entity 'contractures' named entity 'myopathy' named entity 'Muscle function' named entity 'Muscle' named entity 'amyloidosis' named entity 'SLE' named entity 'viruses' named entity 'myositis' named entity 'myositis' named entity 'Staphylococcus aureus' named entity 'myxedema' named entity 'coxsackie' named entity 'Henoch-Schoenlein purpura' named entity 'hypothyroidism' named entity 'muscle weakness' named entity 'myopathy' named entity 'Myositis' named entity 'tetanus' named entity 'myopathy' named entity 'Amyloidosis' named entity 'HIV-1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software